Gilead’s Immunomedics Buy: Five Things To Worry About
Executive Summary
Acquisition is based on the prospects for Immunomedics’ Trodelvy, but regulatory changes, manufacturing challenges, and research dynamics could upset even the best-laid plans.
You may also be interested in...
Trodelvy’s Phase III Breast Cancer Results Raise More Questions Than Answers
Gilead is staying mum about the TROPiCS-02 data, which is fueling speculation that the drug’s benefit may have been modest.
Filgotinib On Uncertain Path As Gilead Regains Speed From Pandemic Hit
Third quarter earnings show Gilead’s Immunomedics buy paid off, but filgotinib’s path may narrow. The HIV and HCV franchises picked up from their COVID-19 lull.
Stockwatch: Can Gilead Wave Its Wand Over Antibody-Drug Conjugates?
After a slow start marked by product withdrawals and toxicity, recent deal-making activity has brought antibody-drug conjugates back from obscurity. But what has changed?